Charlotte Videbaek

Direktor/Vorstandsmitglied bei CESSATECH A/S

62 Jahre

Health Technology

Commercial Services

Consumer Services

Aktive Beziehungen

Name	Geschlecht	Alter	Unternehmensverbindungen	Zusammenarbeit
Adam Sinding Steensberg	M	50	CESSATECH A/S	4 Jahre
Martin Olin	M	55	CESSATECH A/S	4 Jahre
Flemming Steen Jensen	M	63	CESSATECH A/S	4 Jahre
Peter Birk	M	59	CESSATECH A/S	4 Jahre
Jes Trygved	M	51	H. LUNDBECK A/S CESSATECH A/S	8 Jahre
Rachel Curtis Gravesen	F	55	CESSATECH A/S	2 Jahre
Louise Bak	F	-	CESSATECH A/S	3 Jahre

Mehr sehen

Beziehungs-Chart

Beziehungen zu mehreren Unternehmen

Ehemalige Beziehungen

Name	Geschlecht	Alter	Unternehmensverbindungen	Zusammenarbeit
Jakob W. Gotfredsen	M	-	Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	3 Jahre
Ulla Hald Buhl	F	60	CESSATECH A/S	1 Jahre
Uno Jakob Weber	M	-	Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	3 Jahre
Benedikte Bandak	F	-	CESSATECH A/S	-
Jens Peter Balling	M	-	H. LUNDBECK A/S	-
Lars Kober	M	-	Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	3 Jahre
Christian Torp-Pedersen	M	-	Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	3 Jahre
Anders Götzsche	M	56	H. LUNDBECK A/S	15 Jahre
Carsten Schou	M	-	Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	-
Kristian Sibilitz	M	-	H. LUNDBECK A/S	-
Etienne Adriansen	M	60	CESSATECH A/S	-
Steen Henneberg	M	75	CESSATECH A/S	3 Jahre
Bettina Nygaard Nielsen	M	47	CESSATECH A/S	-
Tugba Ceylan	F	-	H. LUNDBECK A/S	1 Jahre
Christoffer Erik Lorenzen	M	48	H. LUNDBECK A/S	5 Jahre
Iman Barilero	M	-	H. LUNDBECK A/S	-
Peter Bisgaard	M	50	Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	-
Marie-Laure Jeanne Antoinette Pochon	F	65	H. LUNDBECK A/S	5 Jahre
Jørgen Okkels Nielsen	M	76	H. LUNDBECK A/S	5 Jahre
Inge Holm Lauritzen	F	57	H. LUNDBECK A/S	9 Jahre
Frank Knudsen	M	66	Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	-
Klaus Bæk Simonsen	M	-	H. LUNDBECK A/S	-
Peter Moldt	M	65	Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	-
Finn Eggert Sørensen	M	70	Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	-
Helle Størum	F	57	H. LUNDBECK A/S	9 Jahre
Hans Henrik Munch-Jensen	M	64	H. LUNDBECK A/S	8 Jahre
Flemming Bent Lindeløv	M	75	H. LUNDBECK A/S	-
Egil Bodd	M	69	H. LUNDBECK A/S	-
Mads Buhl Axelsen	M	66	Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	-
Per Wold-Olsen	M	76	H. LUNDBECK A/S	4 Jahre

Statistik

Land	Beziehungen	% des Gesamten
Dänemark	37	100,00%

Alter der Beziehungen

Aktive

Vergangene

Herr

Frau

Aufsichtsräte

Führungskräfte

Ursprung der Beziehungen

Börse
Insiders
Charlotte Videbaek
Persönliches Netzwerk